Today: 23 January 2026
Subscribe

Goldman Sachs stock slips as bank rally cools, with earnings next week in focus

Goldman Sachs stock slips as bank rally cools, with earnings next week in focus

New York, January 7, 2026, 13:52 (EST) — Regular session Shares of The Goldman Sachs Group Inc (GS.N) fell 1.3% to $942.97 in midday New York trading on Wednesday. The stock opened at $956.88 and swung between $942.00 and $959.68, with about 1.2 million shares traded. Bank stocks slid after a three-session rally as investors digested weaker-than-expected U.S. job openings…
7 January 2026
····
Oklo stock jumps again on DOE radioisotope deal as investor focus shifts to permits

Oklo stock jumps again on DOE radioisotope deal as investor focus shifts to permits

NEW YORK, Jan 7, 2026, 13:54 EST — Regular session Oklo Inc. shares were up about 2.6% at $98.04 in afternoon trade, after swinging between $92.31 and $100.44 earlier in the session. The move followed a company announcement that it signed a DOE “Other Transaction Agreement” — a type of federal contracting vehicle — to support the design, construction and…
7 January 2026
··
Qualcomm stock slips after report flags Samsung 2nm chip talks; earnings next

Qualcomm stock slips after report flags Samsung 2nm chip talks; earnings next

New York, January 7, 2026, 14:36 EST — Regular session QUALCOMM Incorporated shares fell 2.6% to $177.79 on Wednesday afternoon after Chief Executive Cristiano Amon was quoted by the Korea Economic Daily as saying the chip designer is talking first with Samsung Electronics about contract manufacturing of two‑nanometre (2nm) chips. Qualcomm was not immediately available for comment and Samsung said…
7 January 2026
···
RKLB stock price forecast: Rocket Lab slips on insider sales as earnings loom

RKLB stock price forecast: Rocket Lab slips on insider sales as earnings loom

New York, Jan 7, 2026, 14:38 EST — Regular session Rocket Lab Corp shares fell 1.3% to $84.94 in afternoon trade on Wednesday after SEC filings showed CFO Adam C. Spice exercised employee options and sold 1,365,665 shares for about $103.1 million, and chief operations officer Frank Klein sold 100,000 shares for about $7.3 million. Both trades ran under Rule…
7 January 2026
····
BMNR stock forecast: BitMine slides as crypto cools, with a Jan. 14 vote looming

BMNR stock forecast: BitMine slides as crypto cools, with a Jan. 14 vote looming

New York, January 7, 2026, 14:38 EST — Regular session BitMine Immersion Technologies’ shares fell 5.2% to $30.65 in afternoon trading on Wednesday, after swinging between $30.24 and $32.81 earlier in the session. The drop matters now because BMNR has turned into a fast-moving proxy for crypto prices, especially ether, and it heads into a shareholder vote that could reshape…
7 January 2026
····
ASTS stock price forecast: Scotiabank downgrade hits AST SpaceMobile as targets split wide

ASTS stock price forecast: Scotiabank downgrade hits AST SpaceMobile as targets split wide

NEW YORK, Jan 7, 2026, 14:43 EST — Regular session AST SpaceMobile shares slid about 11% on Wednesday after Scotiabank downgraded the satellite-to-smartphone company. The stock was down $10.77 at $86.72 in afternoon trade, after touching $95.25 earlier and a low of $85.37. The drop matters now because ASTS is priced like a timetable. Investors have been leaning on the…
7 January 2026
····
Broadcom stock price forecast: AVGO tests $350 after $4.5B bond pricing and Wi‑Fi 8 launch

Broadcom stock price forecast: AVGO tests $350 after $4.5B bond pricing and Wi‑Fi 8 launch

New York, Jan 7, 2026, 14:36 EST — Regular session Broadcom shares rose 0.9% to $346.8 on Wednesday after a pricing term sheet showed the chipmaker locked in terms for a $4.5 billion, four-part senior notes sale. Coupons run from 4.3% due 2031 to 5.7% due 2056, with spreads of 60 to 88 basis points — 0.60 to 0.88 percentage…
7 January 2026
····
Bitcoin price forecast: $100,000 bets build as BTC slips below $91,000 before U.S. jobs data

Bitcoin price forecast: $100,000 bets build as BTC slips below $91,000 before U.S. jobs data

NEW YORK, January 7, 2026, 14:34 (EST) — Regular session Bitcoin fell on Wednesday, with the world’s largest cryptocurrency down about 1.4% at $90,951. It has traded between $90,629 and $93,734 so far in the session. The pullback lands in a week when macro data are back in charge of the tape, and bitcoin is trading with it. U.S. job…
7 January 2026
····
Oil price forecast: Brent, WTI slide on Trump Venezuela move as 2026 surplus looms

Oil price forecast: Brent, WTI slide on Trump Venezuela move as 2026 surplus looms

New York, Jan 7, 2026, 14:45 (EST) — Regular session Oil prices fell on Wednesday after President Donald Trump said Venezuela would turn over 30 million to 50 million barrels of sanctioned crude to the United States, feeding fears of more supply in an already well-stocked market. Brent crude futures were down 40 cents, or 0.7%, at $60.31 a barrel…
7 January 2026
···
Tesla stock price forecast swings: Wall Street split from $25 to $600 ahead of earnings

Tesla stock price forecast swings: Wall Street split from $25 to $600 ahead of earnings

NEW YORK, Jan 7, 2026, 14:35 EST — Regular session Tesla shares edged higher on Wednesday as fresh price forecasts from Wall Street widened the gap between bulls betting on self-driving and bears focused on the car business. The stock was up about 0.6% at $435.40 in afternoon trade. The calls matter because Tesla is due to report fourth-quarter results…
7 January 2026
····
1 … 435 436 437 438 439 … 2,295

Stock Market Today

  • Genetic Engineering Tool Market Set to Reach $28.57 Billion by 2031 Driven by CRISPR Advances
    January 23, 2026, 6:51 AM EST. The Global Genetic Engineering Tool Market is forecast to grow at a 4.38% CAGR, expanding from $22.09 billion in 2025 to $28.57 billion by 2031. Key growth drivers include rapid technological progress in genome editing platforms like CRISPR-Cas9, which is transitioning from lab research to clinically approved therapies. Notably, the FDA's approval of CASGEVY underscores the commercial viability of gene-edited treatments. Increased funding in biotech and genomics fuels demand for advanced tools and instrumentation. However, stringent regulatory frameworks and ethical concerns over off-target effects delay clinical advances, hindering the shift to large-scale commercial tool procurement. Despite robust investment and nine new product approvals reported in 2024, regulatory hurdles remain a critical challenge for market expansion.
Go toTop